Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702929 | 0.83 | NR1H2 (0.35) | ESR1ESR2NR1H2NR1H3HPGD | |
| SCHEMBL707750 | 0.81 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL1538771 | 0.81 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL24624392 | 0.77 | ESR1 (0.41) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL1538758 | 0.77 | ESR1 (0.41) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL11017962 | 0.77 | ESR1 (0.46) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL8384580 | 0.75 | ESR1 (0.44) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL16751882 | 0.75 | ESR1 (0.39) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL439492 | 0.73 | ESR1 (0.48) | ESR1ESR2NR1H2NR1H3TSHR | |
| SCHEMBL63526 | 0.73 | ESR1 (0.70) | ESR1ESR2NR1H2NR1H3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2011834-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2012-07-25 | — | — | EP | claimed |
| CN-110835354-B | Process for preparing alkyl phenyl fluorosilane | 张家港市国泰华荣化工新材料有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-107428891-B | Curable composition | 施敏打硬株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-105392845-B | Photocurable composition | 思美定株式会社 | 2020-10-20 | — | — | CN | disclosed |
| CN-110835354-A | Process for preparing alkyl phenyl fluorosilane | 张家港市国泰华荣化工新材料有限公司 | 2020-02-25 | — | — | CN | disclosed |
| EP-3081612-B1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | CEMEDINE CO LTD (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9718999-B2 | Photocurable composition having adhesive properties | CEMEDINE CO., LTD (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20160312089-A1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | CEMEDINE CO., LTD. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3081612-A1 | PHOTOCURABLE COMPOSITION HAVING ADHESIVE PROPERTIES | Cemedine Co., Ltd. (JP) | 2016-10-19 | — | — | EP | disclosed |
| US-20160152783-A1 | PHOTOCURABLE COMPOSITION | CEMEDINE CO., LTD. (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20030096793-A1 | Inhibit protease enzymes; Benzyl 5-(benzoylamino)-4,4-dihydroxy-7- methyl-4-sila-octanamide, for example can be used to inhibit HIV protease in the treatment of AIDS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2003-05-22 | — | — | US | disclosed |
| US-6441212-B1 | SILANEDIOL TRIMER OR LARGER MOIETY CONTAINING AT LEAST ONE AMINO OR AMIDO GROUP; ISOSTERES THAT ASPARTIC PROTEASES ACT UPON; NOT CLEAVED UNDER ENZYMATIC CONDITIONS; HUMAN IMMUNODEFICIENCY VIRUS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2002-08-27 | — | — | US | disclosed |
| US-6414173-B1 | TRANSMETALLATION REACTION, COMPRISING: CONTACTING PALLADIUM CATALYST WITH AROYL, ALKANOYL, OR ARALKANOYL ESTER OF ALLYLIC ALCOHOL; AND HYPERVALENT SILICON SPECIES | UNIVERSITY OF MARYLAND | 2002-07-02 | — | — | US | disclosed |
| EP-1019533-A4 | SILANOL ENZYME INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1019533-A1 | SILANOL ENZYME INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5760019-A | INHIBIT PROTEASE ENZYMES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-06-02 | — | — | US | disclosed |
| WO-1998002578-A1 | SILANOL ENZYME INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0285092-B1 | PROCESS TO STRENGTHEN THE ADHERENCE OF POLYMER MATERIALS | Wacker-Chemie GmbH (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4874638-A | PRECOATING AN ALKALINE CARBONATE SURFACE WITH AN APROTIC SOLVENT SOLUTION CONTAINING AN ORGANO SILICON FLUORIDE; DESOLVENTIZING | WACKER-CHEMIE GMBH (DE) | 1989-10-17 | — | — | US | disclosed |
| EP-0285092-A2 | Process to strengthen the adherence of polymer materials | Wacker-Chemie GmbH (DE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096793-A1 | Inhibit protease enzymes; Benzyl 5-(benzoylamino)-4,4-dihydroxy-7- methyl-4-sila-octanamide, for example can be used to inhibit HIV protease in the treatment of AIDS | CTSE, CTSS, DNPEP | ESR1 1180/4885ESR2 1571/4885NR1H2 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.